The Compounding Pharmacy Red Flag Checklist: September 2026 Edition
The criteria that mattered in 2024 are not the criteria that matter now. An updated screening list for a market in the middle of a regulatory wind-down.
The short version
- Shortage-based justifications no longer apply — a provider still citing the shortage as its legal basis is working from an outdated script.
- With the FDA's April 30, 2026 proposal targeting the 503B Bulks List, supply durability now matters as much as price.
- Additive-based personalization is a legal position, not a clinical one, and the FDA has rejected it as a standalone justification.
- The strongest single screening question is simply: which pharmacy fills my prescription?
Guidance written during the shortage told you to check for pharmacy accreditation and compare monthly prices. Both still matter. Neither is sufficient in September 2026, because the central question has changed from is this product good to will this product still exist in six months.
Tier one: stop the transaction
Any one of these is disqualifying on its own.
- No named pharmacy. If nobody will tell you which pharmacy compounds your medication, before or after purchase, do not proceed.
- Product labelled research use only. This is not a prescription pathway. It is a way of selling drugs without pharmacy accountability.
- No clinician interaction at all. A questionnaire that nobody reviews is not medical care.
- Claims of FDA approval. Compounded products are not FDA-approved. In warning letters to telehealth companies in February 2026, the FDA specifically addressed claims implying products had been FDA-approved or evaluated for safety and effectiveness when they had not.
- International shipping of the drug itself. Distinct from a US pharmacy shipping to you domestically.
Tier two: new for the post-shortage era
- Still citing the shortage. The shortages were declared resolved. Marketing that still leans on shortage language is either out of date or deliberately misleading.
- No brand-name pathway. Ask what happens if compounding becomes unavailable. Providers with an answer have thought about it; the two largest telehealth companies both moved toward brand-name supply during 2026.
- Additives with no explanation tied to you. More than 80% of compounded GLP-1 prescriptions contain supplemental ingredients. Ask why yours does, and whether anything about your labs justified it.
- Multidose vial with unit-marked syringes and no written conversion. This is the configuration behind documented 10-fold dosing errors.
Which pharmacy fills my prescription, and can you put that in writing before I pay? A provider that answers cleanly has a supply chain it is willing to stand behind. A provider that deflects is telling you something important.
Tier three: billing and subscription practice
Product quality is not the only failure mode. Reporting on the sector has documented customer complaints about poorly disclosed charges, recurring subscriptions, and obstructed cancellations, including a disputed $866 charge incurred by someone who had registered merely to check pricing. Before you enter payment details:
- Find the cancellation process in writing and confirm it is not phone-only
- Confirm whether the price is monthly or a multi-month commitment billed upfront
- Check whether the advertised price is a first-month promotional rate
- Confirm whether a consultation fee is charged even if you are declined
- Identify the price at higher dose tiers — some programs step up substantially during titration
Providers we currently list, with pricing caveats disclosed
Every provider below is a paid partner. Pricing changes frequently — confirm current cost on the provider's own page before you enrol.
Semaglutide injection through a licensed US telehealth network. Injectable only — no oral formulation offered.
See Embody pricing Paid partner linkMarketplace for cash-pay appointments with clinicians who prescribe FDA-approved brand-name medication only — Rybelsus, the oral Wegovy pill, and Foundayo. No compounded product.
See Sesame Care pricing Paid partner linkSublingual compounded semaglutide drops from about $229/mo.
Offers both injectable and sublingual/buccal compounded options. Sublingual semaglutide runs roughly $199/mo, tirzepatide roughly $299/mo.
See SkinnyRx pricing Paid partner linkTier four: the good signs
Screening is not only about exclusion. Positive indicators worth weighting:
- The compounding pharmacy is named before purchase and verifiable through a state board of pharmacy database
- Certificates of analysis are available on request for your lot
- The full formulation, including additive concentrations, is disclosed in writing
- Dosing instructions are provided in syringe units for your specific vial concentration
- There is a named clinician you can reach for side effect management
- There is an articulated plan for the transition to FDA-approved product
The FDA proposed on April 30, 2026 to remove semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, finding no remaining clinical need for outsourcing facilities to compound them from bulk. Whatever you choose today, choose it knowing the compounded market is contracting rather than expanding.
How to use this list
Run tier one first — it takes two minutes and eliminates most bad actors. Then tier three, because billing complaints are more common than product complaints and easier to verify in advance. Tiers two and four are for choosing between the providers that survive the first two passes.
Sources
- FDA proposed rule on 503B Bulks List status for semaglutide, tirzepatide, and liraglutide, April 30, 2026.
- US Food and Drug Administration warning letters to telehealth companies, February 2026.
- IQVIA analysis of supplemental ingredients in compounded GLP-1 prescriptions.
- America's Poison Centers and FDA data on compounded GLP-1 dosing errors.
- Drug Discovery Trends reporting on telehealth billing and cancellation complaints.
- Medscape coverage of telehealth companies moving toward brand-name GLP-1 supply, 2026.